14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Hold
Today BCRX ranks #2612 as hold candidate. Get a Free Stock at Robinhood
Stronger Stock

BioCryst Pharmaceuticals Stock Forecast NASDAQ:BCRX

$12.21 (9.21%)

Volume: 3M

Closed: Dec 07, 2021

Hollow Logo Score: 0.130

BioCryst Pharmaceuticals Stock Forecast

$12.21 (9.21%)

Volume: 3M

Closed: Dec 07, 2021

Score Hollow Logo 0.130
Which way will BCRX go? Request
Stop-loss: $11.79 (-3.48%)
Key Stats
P/E Ratio -9.63
Beta 1.78
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 51 and the stock is currently not being overbought or oversold

On Tuesday BioCryst Pharmaceuticals stock price gained impressive 9.21%
(Updated on Dec 07, 2021)

Hold candidate since 2021-12-07

The BioCryst Pharmaceuticals stock price gained 9.21% on the last trading day (Tuesday, 7th Dec 2021), rising from $11.18 to $12.21. During the day the stock fluctuated 9.78% from a day low at $11.35 to a day high of $12.46. The price has fallen in 7 of the last 10 days and is down by -1.93% for this period. Volume fell on the last day by -712 thousand shares and in total, 3 million shares were bought and sold for approximately $38.01 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -22.50% during the next 3 months and, with a 90% probability hold a price between $8.62 and $10.64 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, December 06, 2021, and so far it has risen 9.21%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. The BioCryst Pharmaceuticals stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $13.03. On a fall, the stock will find some support from the short-term average at $11.78. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Support, Risk & Stop-loss

BioCryst Pharmaceuticals finds support from accumulated volume at $11.87 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.11 between high and low, or 9.78%. For the last week, the stock has had a daily average volatility of 8.39%.

Our recommended stop-loss: $11.79 (-3.48%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 1 days ago.)

Is BioCryst Pharmaceuticals stock A Buy?

BioCryst Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

Current score: 0.130

Predicted Opening Price for BioCryst Pharmaceuticals of Wednesday, December 8, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 8, 2021 Current price
$12.01 $12.21 (Overvalued)
Hold/Accumulate Upgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 04, 2021 "Royal Bank of Canada" gave "$16.00 - $14.00" rating for BCRX. The price target was changed from $11.93 to 3.8%.

Volatility and Risk
Daily Average Volatility: 8.39 %
Overall Risk: Very High High Medium Low Very Low
8.39 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $12.40
Price: $12.21
Support: $11.87

BCRX Insider Trading Show all Trades



Last 100 transactions
Buy: 2 852 634 | Sell: 981 789 (Shares)
Date Action Amount Person Type
Nov 30, 2021 Buy 414 Aselage Steve Common Stock
Nov 30, 2021 Buy 829 Heggie Theresa Common Stock
Nov 30, 2021 Buy 829 Levin Alan G Common Stock
Nov 30, 2021 Buy 1 554 Ingram Robert Alexander Common Stock
Nov 24, 2021 Buy 7 500 Milano Vincent Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 2 852 634 | Sell: 981 789 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 13.12 7.43 %
12.69 3.95 %
12.43 1.81 %
Current price: 12.21
Support 11.58 -5.14 %
11.32 -7.28 %
10.90 -10.76 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 13.73 12.45 %
12.45 1.97 %
12.40 1.56 %
Current price 12.21
Support 11.87 -2.78%
11.61 -4.91%
11.18 -8.44%

Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE